Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.17
+0.96 (8.56%)
At close: Mar 9, 2026, 4:00 PM EDT
12.35
+0.18 (1.48%)
After-hours: Mar 9, 2026, 7:26 PM EDT
Generate Biomedicines Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Net Income | -203.15 | -173.77 |
| Depreciation & Amortization | 13.18 | 15.35 |
| Loss (Gain) From Sale of Assets | -0.06 | -0.01 |
| Loss (Gain) From Sale of Investments | -2.78 | -5.45 |
| Stock-Based Compensation | 20.58 | 19.47 |
| Other Operating Activities | -13.76 | -1.45 |
| Change in Accounts Receivable | 0.31 | -0.21 |
| Change in Accounts Payable | -2.13 | 3.5 |
| Change in Unearned Revenue | -31.89 | 34.54 |
| Change in Other Net Operating Assets | 19.1 | -9.71 |
| Operating Cash Flow | -200.62 | -117.75 |
| Capital Expenditures | -3.51 | -3.45 |
| Sale of Property, Plant & Equipment | - | 0.01 |
| Investment in Securities | 120.28 | -54.29 |
| Investing Cash Flow | 116.77 | -57.73 |
| Long-Term Debt Repaid | -8.16 | -11.12 |
| Net Debt Issued (Repaid) | -8.16 | -11.12 |
| Issuance of Common Stock | 1.1 | 1.13 |
| Other Financing Activities | 13.12 | 5 |
| Financing Cash Flow | 28.06 | 91.33 |
| Net Cash Flow | -55.79 | -84.15 |
| Free Cash Flow | -204.13 | -121.2 |
| Free Cash Flow Margin | -640.06% | -592.39% |
| Free Cash Flow Per Share | -4.08 | -2.49 |
| Cash Income Tax Paid | 0.16 | 0.21 |
| Levered Free Cash Flow | -119.1 | - |
| Unlevered Free Cash Flow | -118.39 | - |
| Change in Working Capital | -14.62 | 28.12 |
Source: S&P Capital IQ. Standard template.
Financial Sources.